[Retracted] Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

Table 2

Baseline features of 25 patients with AML/MDS.

Serial number	Gender	Age	FAB classification	IPSS-R	Score ECOG score	Transfusion dependence	Previous treatment
1	Man	71	M4a	—	1	Not	Not
2	Man	75	M5b	—	4	Not	Not
3	Woman	59	Hybrid	—	3	Be	Not
4	Woman	55	M5b	—	1	Be	Not
5	Woman	29	M2a	—	0	Be	Not
6	Woman	50	M5b	—	2	Be	Not
7	Woman	68	M5b	—	2	Be	Not
8	Woman	68	M5b	—	1	Not	Not
9	Man	45	M5b	—	1	Not	Not
10	Woman	62	M5b	—	1	Be	Not
11	Woman	58	M5b	—	0	Not	Not
12	Woman	63	M2a	—	1	Be	Not
13	Woman	80	M2a	—	2	Not	Not
14	Woman	64	MDS-EB-2	Risk	4	Be	Not
15	Woman	66	MDS-EB-2	Very low risk	2	Be	Not
16	Man	67	MDS-EB-1	Low risk	1	Not	Not
17	Man	68	MDS-EB-2	Medium-risk	1	Be	Not
18	Man	73	MDS-EB-2	Low risk	1	Be	Not
19	Man	53	MDS-EB-1	Medium-risk	2	Not	Not
20	Woman	57	MDS-EB-2	Risk	4	Be	Not
21	Woman	71	MDS-EB-1	Risk	3	Be	Not
22	Woman	60	MDS-EB-2	Medium-risk	3	Not	Not
23	Man	51	MDS-EB-1	Risk	2	Be	Not
24	Woman	65	MDS-EB-2	Low risk	1	Be	Not
25	Man	48	MDS-EB-2	Risk	3	Be	Not